抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. P選擇素糖蛋白配體1抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴(lài)氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

產(chǎn)品訂購(gòu)信息：
英文名稱(chēng)  Anti-PSGL-1/CD162 

中文名稱(chēng)   P選擇素糖蛋白配體1抗體品牌 

別    名  CD 162; CD162; CD162 antigen; CLA; Cutaneous lymphocyte associated associated antigen; P selectin glycoprotein ligand 1; P selectin glycoprotein ligand 1 precursor; P-selectin glycoprotein ligand 1; PSGL 1; PSGL-1; PSGL1; Selectin P ligand; SELPL_HUMAN; SELPLG.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來(lái)源   Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human 

產(chǎn)品類(lèi)型   一抗  

研究領(lǐng)域    細(xì)胞生物 免疫學(xué) 細(xì)胞粘附分子 細(xì)胞表面分子

蛋白分子量  predicted molecular weight: 41kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human PSGL-1 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

P選擇素糖蛋白配體1抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 This gene encodes a glycoprotein that functions as a high affinity counter-receptor for the cell adhesion molecules P-, E- and L- selectin expressed on myeloid cells and stimulated T lymphocytes. As such, this protein plays a critical role in leukocyte trafficking during inflammation by tethering of leukocytes to activated platelets or endothelia expressing selectins. This protein requires two post-translational modifications, tyrosine sulfation and the addition of the sialyl Lewis x tetrasaccharide (sLex) to its O-linked glycans, for its high-affinity binding activity. Aberrant expression of this gene and polymorphisms in this gene are associated with defects in the innate and adaptive immune response. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Apr 2011].

Function : A SLe(x)-type glycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. PSGL1 is critical for the initial leukocyte capture.

Subunit : Homodimer; disulfide-linked. Interaction with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Sulfation on Tyr-51 of PSGL1 is most important for high affinity L-selectin/SELL binding while P-selectin/SELP requires sulfation on Tyr-48. E-selectin/SELE binds with much lower affinity and requires the sLe(x) epitope, but apparantly not tyrosine sulfation. Dimerization appears not to be required for P-selectin/SELP binding. Interacts with SNX20. Interacts with MSN and SYK; mediates the activation of SYK by SELPLG.

Subcellular Location : Membrane; Single-pass type I membrane protein.

Post-translational modifications : Displays complex, core-2, sialylated and fucosylated O-linked oligosaccharides, at least some of which appear to contain poly-N-acetyllactosamine with varying degrees of substitution. Mainly disialylated or neutral forms of the core-2 tetrasaccharide, Galbeta1-->4GlcNAcbeta1-->6(Galbeta1-->3)GalNAcOH. The GlcN:GalN ratio is approximately 2:1 and the Man:Fuc ratio 3:5. Contains about 14% fucose with alpha-1,3 linkage present in two forms: One species is a disialylated, monofucosylated glycan, and the other, a monosialylated, trifucosylated glycan with a polylactosamine backbone. The fucosylated forms carry the Lewis antigen and are important for interaction with selectins and for functioning in leukocyte rolling. The modification containing the sialyl Lewis X glycan is on Thr-57. No sulfated O-glycans. Some N-glycosylation.

Sulfation, in conjunction with the SLe(x)-containing glycan, is necessary for P- and L-selectin binding. High affinity P-selectin binding has a preferred requirement for the isomer sulfated on both Tyr-48 and Tyr-51, whereas L-selectin binding requires predominantly sulfation on Tyr-51 with sulfation on Tyr-48 playing only a minor role. These sulfations play an important role in L- and P-selectin-mediated neutrophil recruitment, and leukocyte rolling.

DISEASE : Defects in SELP may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.

Similarity : Belongs to the selectin/LECAM family.

Contains 1 C-type lectin domain.

Contains 1 EGF-like domain.

Contains 8 Sushi (CCP/SCR) domains.

Database links : UniProtKB/Swiss-Prot: Q14242.1

PSGL-1廣泛分布于免疫細(xì)胞表面，在生物體內(nèi)可與P、L、E選擇素結(jié)合。在發(fā)生、發(fā)展中有重要作用.

抗體的鑒定：

1）P選擇素糖蛋白配體1抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線(xiàn),計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。

NAP-2/CXCL7(Human neutrophil activating protein-2) ELISA Kit 人中性粒細(xì)胞趨化蛋白2Multi-class antibodies規(guī)格： 48T

Anti-CXCL4/PF-4 血小板因子4抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh MMP-9 基質(zhì)金屬蛋白酶-9抗體 規(guī)格 0.1ml

MMP-13(Human Matrix metalloproteinase 13) ELISA kit 人基質(zhì)金屬蛋白酶13 96T

RSL1D1 英文名稱(chēng)： 細(xì)胞衰老抑制基因蛋白抗體 0.2ml

phospho-Cdc6 (Ser54) 英文名稱(chēng)： 磷酸化細(xì)胞分裂周期蛋白6抗體 0.1ml

Anti-CXCL4/PF-4 血小板因子4抗體Multi-class antibodies規(guī)格： 0.2ml

PIBF(progesterone induced blocking factor) 孕激素誘導(dǎo)阻斷因子(抗原)Multi-class antibodies規(guī)格： 0.5mg

Anti-CD57 CD57抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh P21/CDKN1A p21蛋白抗體 規(guī)格 0.1ml

TNFRSF19 Kit Mouse 小鼠 TNFRSF19 / TROY ELISA配對(duì)抗體 ELISA

TRIB1 英文名稱(chēng)： G蛋白偶聯(lián)誘導(dǎo)蛋白2受體抗體 0.2ml

COLEC10(liver) 英文名稱(chēng)： 凝集蛋白家族10抗體(肝) 0.2ml

Anti-CD57 CD57抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-HCV-NS4a/FITC 熒光素標(biāo)記病毒-NS4a抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Phospho-Paxillin (Tyr118)/FITC 熒光素標(biāo)記磷酸化樁蛋白Paxillin抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh BAG5 BCL2分子伴侶調(diào)節(jié)蛋白5抗體 規(guī)格 0.2ml

ALK (Anaplastic Lymphoma Kinase)(CD246Ag) 間變型激酶(抗原) 0.5mg

GBP2 英文名稱(chēng)： G蛋白結(jié)合蛋白2抗體 0.1ml

Rhesus antibody Rh Rabbit anti-Rat IgG whole serum 兔抗大鼠IgG抗血清 規(guī)格 1ml

Anti-Phospho-Paxillin (Tyr118)/FITC 熒光素標(biāo)記磷酸化樁蛋白Paxillin抗體IgGMulti-class antibodies規(guī)格： 0.2ml

大鼠基質(zhì)金屬蛋白酶3(MMP-3)ELISA 試劑盒 96T/48T 試劑盒 組裝/原裝

人鞘氨醇(SPH)免疫試劑盒 Human Sphingosine,SPH Elisa Kit

MouseMethemoglobin,MHBELISAKit小鼠高鐵血紅蛋白(MHB)ELISA試劑盒規(guī)格：96T/48T

PAR-1蛋白表達(dá)西方雜交分析試劑盒5次

humanoncoproteininducedanscript3,OIT3ELISA試劑盒人癌蛋白誘導(dǎo)轉(zhuǎn)錄物3(OIT3)ELISA試劑盒規(guī)格：96T/48T

Humaecombinationactivatinggene1,RAG-1ELISAKit人重組激活基因1(RAG-1)ELISA試劑盒規(guī)格：96T/48T

大鼠β半乳糖苷酶(βGAL)ELISA試劑盒 ，英文名： βGAL ELISA Kit

Rabbit endothelial niic oxide syhase 3 (eNOS-3) ELISA Kit 兔子內(nèi)皮型合成酶3(eNOS-3)ELISA試劑盒

ELISA 小鼠骨保護(hù)素配體(mouse OPGL) 48T/96T 進(jìn)口分裝

CLIAKitforIL-1Beta(HumanIerleukin1Beta)ELISAKit人白介素1β(IL-1B)規(guī)格：48T/96T

通用型牛(BovineLeukemiaVirus/EnzooticBovineLeukosis;BLV/EBL)試劑盒20次

ELISAKitAng-Ⅰ大鼠緊張素Ⅰ規(guī)格：48T/96T

P選擇素糖蛋白配體1抗體品牌 大鼠白介素7受體(IL-7R)ELISA試劑盒 ，英文名： IL-7R ELISA Kit

Mouse ierleukin 16 (IL-16) ELISA Kit 小鼠白介素16(IL-16)ELISA試劑盒

ELISA 小鼠心肌轉(zhuǎn)錄因子3(mouse GATA3) 48T/96T 進(jìn)口分裝

CLIAKitforIP-10/CXCL10(Humanierferon-inducibleprotein10)ELISAKit人干擾素誘導(dǎo)蛋白10規(guī)格：48T/96T

通用型福氏志賀氏菌(Shigellaflexneri)試劑盒20次

ELISAKitLp-α大鼠脂蛋白α規(guī)格：48T/96T